Leiden, the Netherlands, December 8, 2025: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) today announced its participation in the Oppenheimer Movers in Rare Disease Summit ...

European STOXX Europe 600 Index edges closer to record highs, optimism about future earnings and economic prospects is creating a favorable backdrop for investors. Penny stocks, although an outdated ...

Pharming Group NV stock reached a significant milestone, hitting a 52-week high at 17.89 USD. According to InvestingPro data, the stock is currently trading at 17.94 USD, slightly above this recent ...

Pharming has agreed a deal to sell a recently awarded priority review voucher (PRV) to Novartis for around $21 million - well below the market rate. The price of PRVs, which can be used to shorten the ...

Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, Dec. 22: Impala Platinum Holdings Limited IMPUY: This precious metals mining company has a ...

CSL Behring has filed a lawsuit against a former employee, claiming he stole sensitive information with the intention of passing it on to his new company. The suit in the US District Court for the ...

Stock market trading during the 2025 calendar year has been dominated across Europe by artificial intelligence (AI), with the ...

In this video, Jonathan A. Bernstein, MD, discusses his American College of Allergy, Asthma & Immunology Annual Scientific ...

Pharming Group NV is a holding company, which engages in the development of pharmaceutical products for the treatment of rare diseases and unmet medical needs. The firm offers RUCONEST, which is a ...

) has been revised to $14.94 / share. This is a decrease of 29.86% from the prior estimate of $21.30 dated September 29, 2025. The price target is an average of many targets provided by analysts. The ...